Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Farmers Insurance
US Army
Medtronic
Healthtrust
Teva
Colorcon
Argus Health
Novartis
Covington

Generated: January 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,513,247

« Back to Dashboard

Which drugs does patent 8,513,247 protect, and when does it expire?

Patent 8,513,247 protects MIRVASO and is included in one NDA.

This patent has sixty-three patent family members in twenty-four countries.
Summary for Patent: 8,513,247
Title:Methods and compositions for safe and effective treatment of erythema
Abstract: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier.
Inventor(s): Graeber; Michael (Lawrenceville, NJ), Loesche; Christian (Valbonne, FR), Freidenreich; Philip (Yardley, PA), Liu; Yin-Sang (Princeton, NJ), Leoni; Matthew J. (Hampton, NJ)
Assignee: Galderma Laboratories, L.P. (Fort Worth, TX)
Application Number:13/072,096
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 8,513,247

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp MIRVASO brimonidine tartrate GEL;TOPICAL 204708-001 Aug 23, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,513,247

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,993,571 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders ➤ Subscribe
7,439,241 Compounds, formulations, and methods for treating or preventing rosacea ➤ Subscribe
8,557,817 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders ➤ Subscribe
8,426,410 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders ➤ Subscribe
8,859,551 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders ➤ Subscribe
8,513,249 Methods and compositions for safe and effective treatment of erythema ➤ Subscribe
7,838,563 Compounds, formulations, and methods for ameliorating telangiectasias ➤ Subscribe
8,231,885 Compounds, formulations, and methods for ameliorating telangiectasis ➤ Subscribe
8,410,102 Methods and compositions for treating or preventing erythema ➤ Subscribe
8,586,586 Methods and compositions for treating or preventing erythema ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,513,247

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hong Kong 1164126 ➤ Subscribe
Hong Kong 1204996 ➤ Subscribe
Croatia P20150957 ➤ Subscribe
Canada 2824612 ➤ Subscribe
China 1829518 ➤ Subscribe
China 101380321 ➤ Subscribe
China 101426502 ➤ Subscribe
China 101816793 ➤ Subscribe
China 102743380 ➤ Subscribe
China 103298472 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Queensland Health
AstraZeneca
Medtronic
Teva
US Department of Justice
Chinese Patent Office
Healthtrust
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot